These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 29528883)

  • 21. Mortality rate is associated with paliperidone palmitate, risperidone long-acting injection, and oral paliperidone administration.
    Suzuki H; Hibino H; Inoue Y; Takaya A
    Asian J Psychiatr; 2018 Jun; 35():28. PubMed ID: 29751217
    [No Abstract]   [Full Text] [Related]  

  • 22. Case of catatonia associated with paliperidone.
    Tu CY; Chien YL; Huang WL
    Psychiatry Clin Neurosci; 2016 Aug; 70(8):366. PubMed ID: 27241961
    [No Abstract]   [Full Text] [Related]  

  • 23. Pharmacokinetic drug evaluation of paliperidone in the treatment of schizoaffective disorder.
    Macaluso M; Oliver H; Sohail Z
    Expert Opin Drug Metab Toxicol; 2017 Aug; 13(8):871-879. PubMed ID: 28675307
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predicting psychotic relapse following paliperidone discontinuation.
    Suzuki T
    Lancet Psychiatry; 2023 Mar; 10(3):157-158. PubMed ID: 36804062
    [No Abstract]   [Full Text] [Related]  

  • 25. A case of severe hypothermia following three-month administration of paliperidone palmitate: a case report.
    Fernández-Bargiela N; Yáñez-Rubal JC; Vázquez-Ventoso C; Cid-Silva P; Martín-Herranz I
    Actas Esp Psiquiatr; 2020 Jul; 48(4):181-90. PubMed ID: 32920784
    [No Abstract]   [Full Text] [Related]  

  • 26. Paliperidone Palmitate Once-Monthly Injectable Treatment for Acute Exacerbations of Schizoaffective Disorder.
    Fu DJ; Turkoz I; Simonson RB; Walling D; Schooler N; Lindenmayer JP; Canuso C; Alphs L
    J Clin Psychopharmacol; 2016 Aug; 36(4):372-6. PubMed ID: 27322760
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lower risk for body weight gain and better control of appetite after switching risperidone to paliperidone in a schizoaffective patient.
    Hou YC; Lai CH
    J Neuropsychiatry Clin Neurosci; 2014 Apr; 26(2):E36-7. PubMed ID: 24763786
    [No Abstract]   [Full Text] [Related]  

  • 28. Toxic Epidermal Necrolysis Related to Paliperidone Palmitate: First Case Report.
    Struye A; Depuydt C; Abdel Sater E; Dubois V
    J Clin Psychopharmacol; 2016 Jun; 36(3):279-82. PubMed ID: 26928057
    [No Abstract]   [Full Text] [Related]  

  • 29. Dose-Dependent Paliperidone Associated With Angioedema.
    Yucel A; Yucel N; Ozcan H; Saritemur M
    J Clin Psychopharmacol; 2015 Oct; 35(5):615-6. PubMed ID: 26125544
    [No Abstract]   [Full Text] [Related]  

  • 30. Angioedema Associated With Long-Acting Injectable Paliperidone Palmitate: A Case Report.
    Papadopoulou A; Gkikas K; Efstathiou V; Gkikas I; Kokoris S; Lagari V; Papageorgiou C; Douzenis A; Siafakas N; Rizos EN
    J Clin Psychopharmacol; 2017 Dec; 37(6):730-732. PubMed ID: 29028688
    [No Abstract]   [Full Text] [Related]  

  • 31. Emergence of neuroleptic malignant syndrome while switching between risperidone and paliperidone.
    Teng PR; Lane HY
    J Neuropsychiatry Clin Neurosci; 2011; 23(4):E16-7. PubMed ID: 22231327
    [No Abstract]   [Full Text] [Related]  

  • 32. Atypical Neuroleptic Malignant Syndrome Associated With Paliperidone Long-Acting Injection: A Case Report.
    Langley-DeGroot M; Joshi Y; Lehman D; Rao S
    J Clin Psychopharmacol; 2016 Jun; 36(3):277-9. PubMed ID: 27043124
    [No Abstract]   [Full Text] [Related]  

  • 33. [Atrioventricular block induced by high-dose risperidone].
    Rodríguez-García E; Oscariz-Collar L
    Farm Hosp; 2007; 31(6):385-7. PubMed ID: 18348673
    [No Abstract]   [Full Text] [Related]  

  • 34. The Delirium Related to Oral Paliperidone in Dementia: A Case Report.
    Tsai MC; Chang PT; Yang CH; Liu ME
    J Clin Psychopharmacol; 2016 Apr; 36(2):184-5. PubMed ID: 26872118
    [No Abstract]   [Full Text] [Related]  

  • 35. Real-world data on paliperidone palmitate for the treatment of schizophrenia and other psychotic disorders: a systematic review of randomized and nonrandomized studies.
    Emsley R; Parellada E; Bioque M; Herrera B; Hernando T; García-Dorado M
    Int Clin Psychopharmacol; 2018 Jan; 33(1):15-33. PubMed ID: 28817397
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Solubilized delivery of paliperidone palmitate by D-alpha-tocopheryl polyethylene glycol 1000 succinate micelles for improved short-term psychotic management.
    Muthu MS; Sahu AK; Sonali ; Abdulla A; Kaklotar D; Rajesh CV; Singh S; Pandey BL
    Drug Deliv; 2016; 23(1):230-7. PubMed ID: 24853962
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Paliperidone Palmitate-Induced Delirium in an Adolescent with Schizophrenia: Case report.
    Mirza H; Harding D; Al-Balushi N
    Sultan Qaboos Univ Med J; 2018 May; 18(2):e208-e210. PubMed ID: 30210852
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A case of tardive dystonia associated with long-acting injectable paliperidone palmitate.
    Ma CH; Chien YL; Liu CC; Chen IM; Lin CH
    Eur Neuropsychopharmacol; 2016 Jul; 26(7):1251-2. PubMed ID: 27130697
    [No Abstract]   [Full Text] [Related]  

  • 39. Recovery outcomes of schizophrenia patients treated with paliperidone palmitate in a community setting: patient and provider perspectives on recovery.
    Williams W; McKinney C; Martinez L; Benson C
    J Med Econ; 2016; 19(5):469-76. PubMed ID: 26671481
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Paliperidone palmitate: factors predicting continuation with treatment at 2 years.
    Taylor DM; Sparshatt A; O'Hagan M; Dzahini O
    Eur Neuropsychopharmacol; 2016 Dec; 26(12):2011-2017. PubMed ID: 27743760
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.